Regentis Biomaterials : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)

About this update from Regentis Biomaterials Ltd.

This Amendment No. 1 to Form 20-F (this "Amendment") amends the annual report on Form 20-F of Regentis Biomaterials Ltd. for the year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 24, 2026 (the "Original Report"). This Amendment is being filed solely to correct formatting errors in the Statements of Comprehensive Income (Loss) on page F-4 and the Statements of Temporary Equity and Shareholders' Equity (Deficit) on page F-5 of the Original Report which were mistakenly included in the Original Report due to an oversight by the Company's financial printer. As required by Rule 12b-15 under the Exchange Act, as amended, new certifications by our principal executive officer and principal financial officer are being filed as Exhibits 12.1, 12.2, 13.1 and 13.2 to this Amendment. This Amendment does not reflect events occurring after the filing of the Original Report and does not modify or update the disclosure therein in any way except as described above or herein. No other changes have been made to the Original Report. The filing of this Amendment should not be understood to mean that any statements contained in the Original Report, as amended by this Amendment, are true or complete as of any date subsequent to the original filing date of the Original Report. Unless otherwise stated herein, all disclosures referenced as being made "as of the date of this Annual Report" or similar language are speaking as of the date of the Original Report.

View stock analysis, news, and events for Regentis Biomaterials Ltd.